SYNTHESIS AND USE OF 3-AMINO-4-PHENYL-2-PIPERIDONES AND 4-AMINO-2-BENZAZEPIN-3-ONES AS CONFORMATIONALLY RESTRICTED PHENYLALANINE ISOSTERES IN RENIN INHIBITORS

被引:33
作者
DELASZLO, SE
BUSH, BL
DOYLE, JJ
GREENLEE, WJ
HANGAUER, DG
HALGREN, TA
LYNCH, RJ
SCHORN, TW
SIEGL, PKS
机构
[1] MERCK SHARP & DOHME LTD,DEPT MOLEC SYST,RAHWAY,NJ 07065
[2] MERCK INST THERAPEUT RES,DEPT PHARMACOL,W POINT,PA 19486
关键词
D O I
10.1021/jm00083a006
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The design of P2-P3 conformational restrictions in renin inhibitors by the use of a renin computer graphic model led to the synthesis of inhibitors containing N-Boc, N-acetyl, and N-phthalyl derivatives of 3(S)-amino-4(R,S)-2-piperidones and 4(S)-amino-2-benzazepinones in place of phenylalanine in the control compound N-acetyl-L-phenylalanyl-N-[4(S)-[(butylamino)carbonyl]-1(S)-(cyclohexylmethyl)-2(S)-hydroxy-5-methylhexyl]-L-norleucinamide (32). The piperidone inhibitors were prepared by utilization of the Evans chiral auxilliary to introduce the amino group with enantioselectivity and also to act as a leaving group in an intramolecular cyclization to the piperidone. The most potent inhibitor, 3(S)-(acetylamino)-alpha(S)-butyl-N-[4(S)-[butylamino)carbonyl]-1(S)-(cyclohexylmethyl)-2(S)-hydroxy-5-methylhexyl]-2-oxo-4(R)-phenyl-1-piperidineacetamide (18, IC50 = 21 nM), was 25-fold less potent than the acyclic control 32. Considerable dependence of potency with the size of the P4 derivative was observed as had been expected based on the presynthetic modeling studies. Attempts to rationalize the observed potencies on the basis of further molecular modeling studies suggested that the loss in inhibitor potency was due to the conformational restrictions distorting the 3S center from the geometry present in the putative extended conformation present when the inhibitor is bound within the renin active site.
引用
收藏
页码:833 / 846
页数:14
相关论文
共 37 条
[31]   ON SIZE OF ACTIVE SITE IN PROTEASES .I. PAPAIN [J].
SCHECHTER, I ;
BERGER, A .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1967, 27 (02) :157-+
[32]   STRUCTURE OF RECOMBINANT HUMAN RENIN, A TARGET FOR CARDIOVASCULAR-ACTIVE DRUGS, AT 2.5 A RESOLUTION [J].
SIELECKI, AR ;
HAYAKAWA, K ;
FUJINAGA, M ;
MURPHY, MEP ;
FRASER, M ;
MUIR, AK ;
CARILLI, CT ;
LEWICKI, JA ;
BAXTER, JD ;
JAMES, MNG .
SCIENCE, 1989, 243 (4896) :1346-1351
[33]  
SMITH GM, 1984, DRUG INF J, V18, P167
[34]   STRUCTURE AND REFINEMENT AT 1.8-A RESOLUTION OF THE ASPARTIC PROTEINASE FROM RHIZOPUS-CHINENSIS [J].
SUGUNA, K ;
BOTT, RR ;
PADLAN, EA ;
SUBRAMANIAN, E ;
SHERIFF, S ;
COHEN, GH ;
DAVIES, DR .
JOURNAL OF MOLECULAR BIOLOGY, 1987, 196 (04) :877-900
[35]   DESIGN AND SYNTHESIS OF A POTENT AND SPECIFIC RENIN INHIBITOR WITH A PROLONGED DURATION OF ACTION INVIVO [J].
THAISRIVONGS, S ;
PALS, DT ;
HARRIS, DW ;
KATI, WM ;
TURNER, SR .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (10) :2088-2093
[36]   CONFORMATIONALLY CONSTRAINED RENIN INHIBITORY PEPTIDES - GAMMA-LACTAM-BRIDGED DIPEPTIDE ISOSTERE AS CONFORMATIONAL RESTRICTION [J].
THAISRIVONGS, S ;
PALS, DT ;
TURNER, SR ;
KROLL, LT .
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (07) :1369-1376
[37]   RECENT DEVELOPMENTS IN THE DESIGN OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS [J].
WYVRATT, MJ ;
PATCHETT, AA .
MEDICINAL RESEARCH REVIEWS, 1985, 5 (04) :483-531